Antegrade Medical Announces the Closing of a $7.3M Seed Financing
Quebec City, Quebec, October 28, 2025 – Antegrade Medical Inc. (“Antegrade”), a new Quebec-based medical device company, announces the closing of a CAD $7.3 million Series Seed financing. This financing will support the development of minimally invasive instruments for interventional cardiology procedures.
The financing was led by Sectoral Asset Management through its Fonds Medtech Ventures. In addition, Genesys Capital, Desjardins Capital through the Desjardins Regional and Cooperative fund, Seido Capital, and private investors also participated in this first financing round. "With the emergence of complex and high-risk procedures in the field of structural heart, valve disease, and heart failure, Antegrade is developing dedicated minimally invasive tools to facilitate highly complex interventions and improve safety. The therapeutic strategy proposed by Antegrade aligns with the natural evolution of the field to improve outcomes for a very large and growing population of patients," said Dr. Philippe Généreux, cofounder and Chief Medical Officer and Director of the Structural Heart Program at the Gagnon Cardiovascular Institute within Morristown Medical Center, NJ, USA.
Antegrade is led by Louis Laflamme, CPA, President and CEO, and welcomes Marc-André Marcotte, Partner at Sectoral, Dr. Sarah Farr, Principal at Genesys, and Michel Lussier, External Representative to the Board of Directors. Mr. Laflamme previously led cardiology company OpSens Inc. through its CAD $345 million acquisition by Haemonetics. The company is also co-founded by Dr. Gennaro Giustino as Chief Clinical Officer. Dr. Giustino is an interventional cardiologist with Morristown Medical Center, NJ, USA pioneering novel techniques in complex structural heart procedures and mechanical cardiocirculatory support. Louis Laflamme commented on the financing, “Such a significant seed investment highlights the transformative potential of our clinical approach and the vast opportunity it addresses. This financing will enable Antegrade to accelerate its R&D activities and complete its First-in-Human experience”. “We firmly believe that there are better ways to treat patients suffering from cardiogenic shock and structural heart disease. Hence, we are therefore enthusiastic about supporting Antegrade as they develop innovative solutions poised to transform clinical practice and establish a new benchmark for patient care.” Said Marc-André Marcotte, Partner at Sectoral Asset Management.
About Antegrade Medical Inc.
Antegrade Medical Inc. is an innovative company dedicated to the development of medical instruments that will enable an antegrade approach to treating advanced and high-risk patients requiring interventional cardiology procedures.
About Sectoral Asset Management and Fonds Medtech Ventures
Sectoral specializes in managing public equities and venture capital investment strategies in the healthcare sector. In 2023, the firm established the Fonds Medtech Ventures (FMV), an initiative specifically dedicated to companies operating in the field of medical technologies. Driven by a commitment to foster innovation, the FMV primarily invests in early-stage Canadian companies and strives to be an integral partner in their journey to become leaders in the Medtech sector.
About Genesys Capital
Genesys Capital is a venture capital firm based in Toronto, investing in early-stage life sciences opportunities in areas of unmet medical need. With over 25 years of experience adhering to a consistent strategy, Genesys has a proven track record of identifying emerging opportunities and transforming them into commercially successful companies. The firm has generated more than 20 exits and is currently investing from Genesys Ventures IV.
About Desjardins Capital
As a fund manager, Desjardins Capital partners with investors to create entrepreneurial wealth and contribute to collective prosperity. For over 50 years, this investment partner has provided tailored support to businesses to support regional socioeconomic growth in Quebec. With $3 billion in assets under management and the strength of Desjardins networks, it leverages its responsible and efficient management and its integrated, human approach to support sustainable community development.
About Seido Capital
Seido Capital is a startup and growth investor in the healthcare sector, active in North America, with 150 million dollars in assets under management. With 20 years of experience and a top-quartile track record, we collaborate with visionary entrepreneurs to tackle major challenges through groundbreaking innovations in biotechnology, medical devices, and AI tools for the life sciences sector.
Forward-looking statements contained in this press release involve known and unknown risks, uncertainties and other factors that may cause actual results, performance and achievements of Antegrade Medical inc. to be materially different from any future results, performance or achievements expressed or implied by the said forward-looking statements.
For further information, please contact:
Louis Laflamme, CPA, CA, President and CEO, 418.951.2420